Morningstar’s analyst picks ResMed and PWR as top ASX long-term plays, with ResMed eyeing sleep market domination.

With pending news flow of significance coming in 2025, these ASX-listed gas companies could be worth putting on your radar.

Gold outshined the chasing pack as only a handful of commodities sailed through choppy economic waters unscathed in a ...

Aussies are missing out on hundreds of thousands of dollars in superannuation returns, according to one of the nation’s largest super funds.

Brazilian Critical Minerals is looking forward to a big 2025 in which the market sees the value of its Ema rare earths ...

Gold prices rose ~1.5% on Thursday and Friday, following on from a ~26% annual gain, the metal's ninth best in 50 years.

Large and medium-sized Aussie firms must report climate risks from 2025, giving investors more transparency on what’s coming.

Elevate Uranium, Bannerman Energy and Lotus Resources have made some of the biggest gains amongst the uranium companies ...

The ASX's strong performance last year means investors need to dig deeper for value – and the small to mid cap sector is the ...

The ASX rose on Friday on oil and uranium supply issues. Meanwhile the Aussie dollar slipped as gold and real estate climbed.

The co-developer of a US-approved drug, Professor Andrew Wilks has formed Synthesis Bioventures to sniff out more winners.

New data shows the 40 key ASX biotechs gained an average 50% in 2024 - but not all of them joined the winner's circle.